https://www.sublocadehcp.com/component---src-pages-404-js-94758687be64f935d28e.js

1"use strict";(self.webpackChunkindivior_sublocade_hcp=self.webpackChunkindivior_sublocade_hcp||[]).push([[5125],{3331:function(e,i,t){t.r(i);t(6540);var n=t(6321),o=t(5032),r=t(5630),d=t(4985),a=t(2155),s=t(4809),m=t(7437);var p={name:"1x89cvs",styles:"@media (min-width: 1024px){display:none;}"},l={name:"sry5x7",styles:"@media (min-width: 1280px){display:none;}"},c={name:"mckxb1",styles:"--tw-bg-opacity:1;background-color:rgb(32 53 104 / var(--tw-bg-opacity, 1));padding-top:1.25rem;@media (min-width: 1024px){padding-top:3.125rem;}"},h={name:"1i7jxri",styles:"text-align:center;font-size:1.1875rem;font-weight:600;--tw-text-opacity:1;color:rgb(255 255 255 / var(--tw-text-opacity, 1))"},u={name:"d6yvq9",styles:"margin-top:1.875rem;padding-left:1rem;padding-right:1rem;text-align:center;font-family:'Knockout';font-size:2rem;text-transform:uppercase;line-height:1;--tw-text-opacity:1;color:rgb(255 255 255 / var(--tw-text-opacity, 1));@media (min-width: 1024px){margin-top:4rem;padding-left:0px;padding-right:0px;font-size:2.813rem;line-height:1.5;}"},g={name:"v0qmdn",styles:"margin-bottom:3.125rem;font-size:0.875rem;line-height:1.25rem;@media (min-width: 1024px){margin-bottom:4.375rem;font-size:1rem;line-height:1.5rem;}"};i.default=function(){const e=[(0,m.Y)("span",null,"SUBLOCADE [prescribing information]. North Chesterfield, VA: Indivior Inc."),(0,m.Y)("span",null,"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update [published correction appears in ",(0,m.Y)("em",null,"J Addict Med"),". 2020 May/Jun; 14(3):267]. ",(0,m.Y)("em",null,"J Addict Med"),". 2020;14(2S Suppl 1):1-91. doi:10.1097/​ADM.0000000000000633"),(0,m.Y)("span",null,"Laffont CM, Ngaimisi E, Gopalakrishnan M, et al. Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. ",(0,m.Y)("em",null,"Front Pharmacol"),". 2022;13:1052113. doi:10.3389/​fphar.2022.1052113")],i=[{copy:"Return to homepage",href:"/",addedListStyles:{minWidth:"0px","@media (min-width: 1280px)":{width:"25rem"}},addedLinkStyles:{"@media (min-width: 1280px)":{width:"100%"}}},{copy:(0,m.Y)("span",null,"Discover why ",(0,m.Y)("br",null),"monthly dosing"),href:"/dosing-administration",addedListStyles:{minWidth:"0px","@media (min-width: 1280px)":{width:"25rem"}},addedLinkStyles:{"@media (min-width: 1280px)":{width:"100%"}}},{copy:(0,m.Y)("span",null,"Learn more ",(0,m.Y)("br",{css:p}),"about OUD"),href:"/disease-risks",addedListStyles:{minWidth:"0px","@media (min-width: 1280px)":{width:"25rem"}},addedLinkStyles:{"@media (min-width: 1280px)":{width:"100%"}}}];return(0,m.Y)(n.A,{references:e,skeletonJobcode:"P-BAG-US-01616 Feb 2025"},(0,m.Y)(a.A,{css:l}),(0,m.Y)("section",{css:c},(0,m.Y)(r.A,null,(0,m.Y)("h1",{css:[s.SF,"margin-bottom:1.25rem;font-size:2rem;--tw-text-opacity:1;color:rgb(255 255 255 / var(--tw-text-opacity, 1));@media (min-width: 1024px){margin-bottom:1.875rem;}",""]},"404 Error"),(0,m.Y)("p",{css:h},"Oh no! Are you lost? We're here to help keep you on track."),(0,m.Y)("p",{css:u},"Check out these pages about SUBLOCADE"))),(0,m.Y)(d.d,{pagination:i,addedClass:"error-cta"}),(0,m.Y)(r.A,null,(0,m.Y)("p",{css:g},"OUD=opioid use disorder.")))},t.d(i,["Head",0,()=>(0,m.Y)(o.A,{title:"Error 404 Page Not Found | SUBLOCADE® (buprenorphine extended-release) HCP",description:"Explore our site to learn more about SUBLOCADE. See Safety Info, PI, & Boxed Warning.",noSocial:!0})])}}]);
2//# sourceMappingURL=component---src-pages-404-js-94758687be64f935d28e.js.map